Phathom Pharmaceuticals, Inc. has announced a significant development regarding its drug VOQUEZNA (vonoprazan) following the establishment of a public docket by the U.S. Food and Drug Administration (FDA). This event is crucial as it pertains to the ongoing litigation involving BDR Pharmaceuticals, which has filed an abbreviated new drug application (ANDA) referencing VOQUEZNA.
The FDA's public docket, identified as Docket No. FDA-2026-N-13038, is intended to solicit comments on legal and regulatory questions raised by BDR Pharmaceuticals in its challenge against the FDA's previous decision. This decision acknowledged Phathom's Citizen Petition, which affirmed that VOQUEZNA benefits from 10 years of New Chemical Entity (NCE) exclusivity, extending through May 3, 2032.
Phathom's Chief Legal Officer, Anne Marie Cook, stated, "We believe the FDA carefully reviewed the NCE exclusivity period applicable to VOQUEZNA through a full public process and reached the right decision, which exclusivity remains in effect." The company intends to submit comments to the FDA and defend its position in any court proceedings related to the matter.
Background
Phathom Pharmaceuticals, Inc., incorporated in Delaware, operates in the pharmaceutical preparations sector (SIC 2834). The company is publicly traded on the Nasdaq under the ticker symbol PHAT. Phathom focuses on developing and commercializing innovative treatments for gastrointestinal diseases, with VOQUEZNA being a key product in its portfolio.
In recent filings, Phathom has been actively involved in discussions regarding its regulatory strategies and the status of its products. The latest filing, dated October 26, 2026, highlights the ongoing legal challenges it faces and the importance of regulatory decisions in shaping its business landscape.
What the Filing Says
The filing details the establishment of the FDA public docket and the implications of the ongoing litigation. It states, "The deadline for comments submitted to the public docket is November 23, 2026." Furthermore, it notes that a second ANDA filer, Saba Ilac Sanayii Ve Ticaret AS, has expressed intentions to consolidate its case with BDR's litigation.
Impact
This development may significantly affect Phathom's market position and the competitive dynamics within the pharmaceutical preparations industry. The outcome of the litigation could potentially alter the exclusivity period for VOQUEZNA, allowing competitors to enter the market sooner than anticipated. Phathom's ability to maintain its exclusivity is crucial not only for its revenue but also for its overall business strategy moving forward.
What's Next
Phathom plans to respond to the FDA's public docket by the November 23 deadline. The company is also expected to continue its legal defense against BDR Pharmaceuticals and any related parties involved in the litigation. The filing does not specify any further actions beyond these responses.